NCT04872699 (SPEED-COVID) is a clinical trial of Serology testing, RT PCR in Covid19, sponsored by Centre Hospitalier Sud Essonne.

Who is sponsoring NCT04872699?

NCT04872699 is sponsored by Centre Hospitalier Sud Essonne.

What drugs are being tested in NCT04872699?

Interventions in NCT04872699: Serology testing, RT PCR.

Is NCT04872699 still recruiting?

NCT04872699 is currently status unknown. Last updated 4 May 2021.

Last reviewed 2021-05-04 · How we verify

NCT04872699: SPEED-COVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence of COVID-19 in a French Dependent Care Facility for the Elderly and in a French Long-term Care Unit: Observational Study

Status unknown Last updated 4 May 2021

What this trial tests

trial testing Serology testing, RT PCR in Covid19 in 150 participants. Status unknown.

Timeline

22 April 2021

Primary endpoint
31 May 2021

31 May 2022

Quick facts

Lead sponsor	Centre Hospitalier Sud Essonne
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	22 April 2021
Primary completion	31 May 2021
Estimated completion	31 May 2022
Sites	1 location across France

Drugs / interventions tested

Serology testing, RT PCR

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Centre Hospitalier Sud Essonne

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the prevalence of COVID-19 among the residents and geriatric inpatients of the care facilities attached to the Centre Hospitalier Sud Essonne (a general hospital located in Ile-de-France, France), and the factors that are likely to influence this prevalence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Centre Hospitalier Sud Essonne trials

Trials by the same sponsor.

NCT04548908 — Prevalence Of COVID-19 Among Health-workers in a French General Hospital · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04872699 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Sud Essonne
Last refreshed: 4 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04872699.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing